Up to $225 million: Eli Lilly and Telix Pharmaceuticals reach licensing deal for olaratumab

On April 10, 2022, Telix Pharmaceuticals announced a licensing agreement with Eli Lilly

Olaratumab was originally developed by Eli Lilly as a (non-radiolabeled) monoclonal antibody targeting platelet-derived growth factor receptor alpha (PDGFRα) and was approved by the FDA in October 2016 for the treatment of adult soft tissue sarcoma (STS)

Approved drugs targeting PDGFRα

STS is a malignant tumor originating from adipose, fascia, muscle, fiber and other tissues.

Standard treatments for STS include surgery, radiation therapy, and/or chemotherapy, and for patients with advanced, unresectable, or metastatic disease, treatment typically includes chemotherapy with a single agent (eg, doxorubicin) or an anthracycline-based combination regimen

Telix is ​​a late-stage biopharmaceutical company headquartered in Melbourne, Australia, with international operations in Belgium, Japan, Switzerland and the United States

Original in English: https://telixpharma.